血管炎成都哪家医院好(成都哪家医院能治精索静脉曲张的) (今日更新中)

BEIJING, March 3 (Xinhuanet) -- A new study suggested that regular use of painkiller ibuprofen may cut the risk of developing Parkinson's disease, according to Reuters reports.The research findings were published in the online edition of the journal Neurology on Wednesday and later will appear in the print edition on March 8.The study, which followed more than 136,000 U.S. men and women for six years, showed that people who took ibuprofen at least twice a week were 38 percent less likely to develop Parkinson's, a brain disorder that causes tremors and movement problems, compared to those who didn't take the pain reliever so often.Ibuprofen is sold in the U.S. as a non-steroidal anti-inflammatory drug (NSAID). But the study didn't prove that other NSAIDS, like aspirin or naproxen, could also cut the Parkinson's risk."Our study suggests ibuprofen could be a potential neuroprotective agent against Parkinson's," says lead researcher Dr. Xiang Gao from Harvard Medical School, "Protective effects are seen after taking ibuprofen two or more times a week. That's so-called regular use."However, he also warned that no proof has been found that ibuprofen itself can help ward off Parkinson's, and said that it's too early to recommend people to start taking ibuprofen to protect against the disorder.Gao said, "We just see an association, not some causal relationship."Besides, regular ibuprofen use has risks, like stomach bleeding and kidney damage.

WASHINGTON, May 27 (Xinhua) -- The U.S. Treasury Department said in a report released on Friday that China was not manipulating its currency."In China, since the authorities decided in June 2010 to allow the exchange rate to appreciate in response to market forces, the renminbi (RMB) has appreciated by a total of 5.1 percent against the dollar in nominal terms through the end of April 2011, or at an annual pace of approximately 6.0 percent," noted the semi- annual report on international economic and exchange rate policies.The Treasury said that as inflation in China is significantly higher than it is in the United States, the renminbi has appreciated more rapidly against the dollar on a real, inflation- adjusted basis, at a rate of around 9 percent per year.The delayed report, which was originally scheduled to be sent to the Congress on April 15, finds "no major trading partner of the United States" manipulated its currency during the period covered in the report.The Treasury added that it will continue to "closely monitor" the renminbi appreciation pace.The report also noted that the U.S. economy is recovering from its deepest recession in the post-war period."While recent growth is encouraging, the economy still faces significant challenges," said the report. The number one challenge is still in the labor market.The U.S. unemployment rate, currently at 9.0 percent, is not expected to fall significantly this year.Besides, housing market and long-term fiscal position are " unsustainable," according to the report.In recent remarks, Treasury Secretary Timothy Geithner stated that China is the fastest growing market for U.S. exports. In 2010, U.S. exports to China grew at a pace that was 50 percent higher than the rest of the world.

BEIJING, Jan. 26 (Xinhua) -- Chinese Premier Wen Jiabao Wednesday invited more foreign talents to continue their careers or start businesses in China, pledging better conditions for them.During a seminar with more than 20 veteran foreign experts at the Great Hall of the People a week before the Chinese New Year, Wen thanked the foreign friends for their contributions to China's achievements in 2010.Wen said 2011 is a new starting point for China's modernization, as the country implements its 12th five-year plan for economic and social development."China's development is much more associated with the world and the supply of talents than before," Wen said, adding that China will adopt a more open policy to attract overseas experts.Last year, foreign experts made more than 300,000 visits to China, according to Ji Yunshi, general director of the State Administration of Foreign Experts Affairs.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

来源：资阳报